| Literature DB >> 31329508 |
David F Woodward1,2, Jenny W Wang2, W Daniel Stamer3, E Lütjen-Drecoll4, Achim H-P Krauss5, Carol B Toris6.
Abstract
For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.Entities:
Keywords: EP2 agonists; drug delivery; glaucoma therapy
Year: 2019 PMID： 31329508 DOI： 10.1089/jop.2019.0041
Source DB: PubMed Journal: J Ocul Pharmacol Ther ISSN： 1080-7683 Impact factor: 2.671